Compare Ginkgo Bioworks Holdings Inc (DNA) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Kinross Gold Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Kinross Gold Corporation trades at $24 (market cap $28.24B). The key difference: Kinross Gold Corporation is far larger — about 47.8× Ginkgo Bioworks Holdings Inc's market cap, and Kinross Gold Corporation pays a 0.61% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | KGC | |
|---|---|---|
Market Cap | $590.53M | $28.24B |
Sector | Health | Basic Materials |
52-Week High | $16.14 | $38.06 |
52-Week Low | $5.48 | $15.33 |
Enterprise Value | $627.78M | $26.80B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
KGC trades at $23.48, down 2.73% on the day, amid a bearish technical signal. Fundamentally, the company shows robust health with revenue growth from $3.5B in 2022 to $7.05B in 2025 and a net income margin of 35.99%. Recent quarters have consistently beaten EPS estimates. Analyst consensus is bullish with a $37.20 price target, though technical indicators suggest near-term pressure.
The outlook for KGC is positive based on strong fundamentals and growth trajectory, but investors face near-term technical headwinds and sensitivity to gold prices. The stock presents a value opportunity with a low P/E of 9.99, though execution on production guidance and cost management remain key to realizing upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
